NORMATIVE INSTRUCTION - IN No. 123, OF MARCH 24, 2022
I- essential (I): item that meets the recommendations of good practices for bioavailability/bioequivalence of medicines, which can have a critical
influence on the quality or safety of the tests and on the safety of workers in their interaction with the products and processes during the performance of
studies;
(Published in DOU No. 61, of March 30, 2022)
Ministry of Health - MS
II- necessary (N): item that complies with the recommendations of Good Practices for Bioavailability/Bioequivalence of Medicines, which may
influence, to a lesser extent, the quality or safety of the tests and the safety of workers in their interaction with products and processes during the
performance of studies;
Approves the Inspection Guide for Medicine Bioavailability/Bioequivalence Centers.
National Health Surveillance Agency - ANVISA
This text does not replace the one(s) published in the Official Gazette.
The Collegiate Board of the National Health Surveillance Agency, in the use of the powers conferred by arts. 7, item III, and 15, items III and IV,
of Law No. 9782, of January 26, 1999, and considering the provisions of art. 187, item VII and §§ 1 and 3, of the Internal Regulations, approved by the
Resolution of the Collegiate Board of Directors - RDC No. 585, of December 10, 2021, resolves to adopt the following Normative Instruction, as decided at
a meeting held on March 23 2022, and I, Chief Executive Officer, determine its publication:
Art. 2 For the purposes of this Normative Instruction, the following definitions are adopted:
Art. 1 The inspection roadmap in centers of bioavailability/bioequivalence of medicines, contained in the ANNEX of this Normative Instruction,
pursuant to art. 4 of the Collegiate Board Resolution – RDC No. 56, of October 8, 2014, which provides for the Certification of Good Practices for carrying
out studies of bioavailability/bioequivalence of medicines, or any other that may replace it.
Machine Translated by Google